178 related articles for article (PubMed ID: 15769613)
21. Elimination of both E1 and E2 from adenovirus vectors further improves prospects for in vivo human gene therapy.
Gorziglia MI; Kadan MJ; Yei S; Lim J; Lee GM; Luthra R; Trapnell BC
J Virol; 1996 Jun; 70(6):4173-8. PubMed ID: 8648763
[TBL] [Abstract][Full Text] [Related]
22. NF-κB promotes leaky expression of adenovirus genes in a replication-incompetent adenovirus vector.
Machitani M; Sakurai F; Wakabayashi K; Nakatani K; Shimizu K; Tachibana M; Mizuguchi H
Sci Rep; 2016 Jan; 6():19922. PubMed ID: 26814140
[TBL] [Abstract][Full Text] [Related]
23. Second-generation adenovirus vectors.
Wang Q; Finer MH
Nat Med; 1996 Jun; 2(6):714-6. PubMed ID: 8640568
[No Abstract] [Full Text] [Related]
24. Inhibition of adenovirus cytotoxicity, replication, and E2a gene expression by adeno-associated virus.
Jing XJ; Kalman-Maltese V; Cao X; Yang Q; Trempe JP
Virology; 2001 Dec; 291(1):140-51. PubMed ID: 11878883
[TBL] [Abstract][Full Text] [Related]
25. Targeting the replication of adenoviral gene therapy vectors to lung cancer cells: the importance of the adenoviral E1b-55kD gene.
Hay JG; Shapiro N; Sauthoff H; Heitner S; Phupakdi W; Rom WN
Hum Gene Ther; 1999 Mar; 10(4):579-90. PubMed ID: 10094201
[TBL] [Abstract][Full Text] [Related]
26. Noninvasive visualization of adenovirus replication with a fluorescent reporter in the E3 region.
Ono HA; Le LP; Davydova JG; Gavrikova T; Yamamoto M
Cancer Res; 2005 Nov; 65(22):10154-8. PubMed ID: 16287998
[TBL] [Abstract][Full Text] [Related]
27. Selective replication of E1B55K-deleted adenoviruses depends on enhanced E1A expression in cancer cells.
Zheng X; Rao XM; Snodgrass CL; McMasters KM; Zhou HS
Cancer Gene Ther; 2006 Jun; 13(6):572-83. PubMed ID: 16341141
[TBL] [Abstract][Full Text] [Related]
28. The ups and downs of adenovirus vectors.
Ginsberg HS
Bull N Y Acad Med; 1996; 73(1):53-8. PubMed ID: 8804738
[TBL] [Abstract][Full Text] [Related]
29. Development of a recombinant adenovirus vector production system free of replication-competent adenovirus by utilizing a packaging size limit of the viral genome.
Suzuki T; Sasaki T; Yano K; Sakurai F; Kawabata K; Kondoh M; Hayakawa T; Yagi K; Mizuguchi H
Virus Res; 2011 Jun; 158(1-2):154-60. PubMed ID: 21470569
[TBL] [Abstract][Full Text] [Related]
30. 'Autoreplication' of the vector genome in recombinant adenoviral vectors with different E1 region deletions and transgenes.
Marienfeld U; Haack A; Thalheimer P; Schneider-Rasp S; Brackmann HH; Poller W
Gene Ther; 1999 Jun; 6(6):1101-13. PubMed ID: 10455413
[TBL] [Abstract][Full Text] [Related]
31. A Partial E3 Deletion in Replication-Defective Adenoviral Vectors Allows for Stable Expression of Potentially Toxic Transgene Products.
Haut LH; Gill AL; Kurupati RK; Bian A; Li Y; Giles-Davis W; Xiang Z; Zhou XY; Ertl HC
Hum Gene Ther Methods; 2016 Oct; 27(5):187-196. PubMed ID: 27604324
[TBL] [Abstract][Full Text] [Related]
32. Induction and inhibition of innate inflammatory responses by adenovirus early region proteins.
Schaack J
Viral Immunol; 2005; 18(1):79-88. PubMed ID: 15802954
[TBL] [Abstract][Full Text] [Related]
33. Reduced toxicity, attenuated immunogenicity and efficient mediation of human p53 gene expression in vivo by an adenovirus vector with deleted E1-E3 and inactivated E4 by GAL4-TATA promoter replacement.
Ji L; Bouvet M; Price RE; Roth JA; Fang B
Gene Ther; 1999 Mar; 6(3):393-402. PubMed ID: 10435089
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of E1B gene-attenuated replicating adenoviruses for cancer gene therapy.
Kim J; Cho JY; Kim JH; Jung KC; Yun CO
Cancer Gene Ther; 2002 Sep; 9(9):725-36. PubMed ID: 12189522
[TBL] [Abstract][Full Text] [Related]
35. Construction and characterization of E1-minus replication-defective adenovirus vectors that express E3 proteins from the E1 region.
Toth K; Kuppuswamy M; Doronin K; Doronina O; Lichtenstein D; Tollefson A; Wold W
Virology; 2002 Sep; 301(1):99-108. PubMed ID: 12359450
[TBL] [Abstract][Full Text] [Related]
36. Use of multiply deleted adenovirus vectors to probe adenovirus vector performance and toxicities.
Amalfitano A
Curr Opin Mol Ther; 2003 Aug; 5(4):362-6. PubMed ID: 14513678
[TBL] [Abstract][Full Text] [Related]
37. Development of a size-restricted pIX-deleted helper virus for amplification of helper-dependent adenovirus vectors.
Sargent KL; Ng P; Evelegh C; Graham FL; Parks RJ
Gene Ther; 2004 Mar; 11(6):504-11. PubMed ID: 14999222
[TBL] [Abstract][Full Text] [Related]
38. A cell line for high-yield production of E1-deleted adenovirus vectors without the emergence of replication-competent virus.
Gao GP; Engdahl RK; Wilson JM
Hum Gene Ther; 2000 Jan; 11(1):213-9. PubMed ID: 10646652
[TBL] [Abstract][Full Text] [Related]
39. Generation of adenovirus vectors devoid of all viral genes by recombination between inverted repeats.
Steinwaerder DS; Carlson CA; Lieber A
J Virol; 1999 Nov; 73(11):9303-13. PubMed ID: 10516039
[TBL] [Abstract][Full Text] [Related]
40. Recombinant, replication-defective adenovirus gene transfer vectors induce cell cycle dysregulation and inappropriate expression of cyclin proteins.
Wersto RP; Rosenthal ER; Seth PK; Eissa NT; Donahue RE
J Virol; 1998 Dec; 72(12):9491-502. PubMed ID: 9811682
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
